BR0210994A - Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células - Google Patents
Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e célulasInfo
- Publication number
- BR0210994A BR0210994A BR0210994-8A BR0210994A BR0210994A BR 0210994 A BR0210994 A BR 0210994A BR 0210994 A BR0210994 A BR 0210994A BR 0210994 A BR0210994 A BR 0210994A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical
- tissue
- compounds containing
- cell treatment
- containing nanoparticles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29848601P | 2001-06-15 | 2001-06-15 | |
PCT/US2002/018971 WO2002102311A2 (en) | 2001-06-15 | 2002-06-14 | Nanoparticles for treating targeted tissues and cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210994A true BR0210994A (pt) | 2004-06-08 |
Family
ID=23150732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210994-8A BR0210994A (pt) | 2001-06-15 | 2002-06-14 | Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células |
Country Status (9)
Country | Link |
---|---|
US (4) | US7387790B2 (pt) |
EP (1) | EP1401396A4 (pt) |
JP (2) | JP2005500293A (pt) |
KR (1) | KR100915741B1 (pt) |
BR (1) | BR0210994A (pt) |
CA (1) | CA2449856C (pt) |
IL (2) | IL159119A0 (pt) |
MX (1) | MXPA03011593A (pt) |
WO (1) | WO2002102311A2 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2449856C (en) | 2001-06-15 | 2009-03-10 | Cornerstone Pharmaceuticals | Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
PL1827500T3 (pl) * | 2004-10-26 | 2009-09-30 | Pharma Mar Sa | Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743 |
KR100806669B1 (ko) * | 2005-06-23 | 2008-02-26 | 김정환 | 나노 입자-생체 복합체 |
KR100809402B1 (ko) * | 2007-01-29 | 2008-03-05 | 김정환 | 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법 |
US8263653B2 (en) | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
AU2008242830B2 (en) | 2007-04-18 | 2015-08-20 | Cornerstone Pharmaceuticals, Inc. | Lipoic acid derivatives |
CN102046011A (zh) * | 2008-04-04 | 2011-05-04 | 罗伯特·绍尔 | 微管相互作用剂的脂质-油-水纳米乳递送系统 |
US20110224447A1 (en) * | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
US20100055041A1 (en) * | 2008-08-28 | 2010-03-04 | Dong June Ahn | Nanotracer for in-situ gastric cancer detection |
US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
US10058837B2 (en) | 2009-08-28 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
EP3311827B1 (en) | 2011-10-03 | 2023-01-04 | Canqura Oncology Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
CA2933579A1 (en) | 2013-12-11 | 2015-06-18 | University Of Massachusetts | Compositions and methods for treating disease using salmonella t3ss effector protein (sipa) |
CA2965898C (en) | 2014-06-19 | 2021-07-06 | Robert Shorr | Fatty acid analogs |
AU2014398232B2 (en) | 2014-06-19 | 2019-11-28 | Rafael Pharmaceuticals, Inc. | Pharmaceutical compounds |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684479A (en) * | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
EP0465588A4 (en) * | 1989-04-04 | 1992-06-03 | Alcon Laboratories Inc | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
US5478860A (en) | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
SE9303281D0 (sv) | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
SE9303744D0 (sv) | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
US5549901A (en) | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5616330A (en) | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
JPH0924269A (ja) * | 1995-07-10 | 1997-01-28 | M Technic Kk | リン脂質を使ったマイクロカプセルの製造方法 |
US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
FR2804016B1 (fr) | 2000-01-21 | 2006-07-28 | Oreal | Nanoemulsion contenant des lipides amphiphiles et un ester de peg et utilisations |
CA2449856C (en) * | 2001-06-15 | 2009-03-10 | Cornerstone Pharmaceuticals | Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
-
2002
- 2002-06-14 CA CA002449856A patent/CA2449856C/en not_active Expired - Lifetime
- 2002-06-14 US US10/172,724 patent/US7387790B2/en active Active
- 2002-06-14 BR BR0210994-8A patent/BR0210994A/pt not_active IP Right Cessation
- 2002-06-14 KR KR1020037016158A patent/KR100915741B1/ko not_active IP Right Cessation
- 2002-06-14 EP EP02756195A patent/EP1401396A4/en not_active Withdrawn
- 2002-06-14 JP JP2003504900A patent/JP2005500293A/ja active Pending
- 2002-06-14 MX MXPA03011593A patent/MXPA03011593A/es active IP Right Grant
- 2002-06-14 IL IL15911902A patent/IL159119A0/xx active IP Right Grant
- 2002-06-14 WO PCT/US2002/018971 patent/WO2002102311A2/en active IP Right Grant
-
2003
- 2003-11-27 IL IL159119A patent/IL159119A/en unknown
-
2004
- 2004-10-27 US US10/974,892 patent/US7220428B2/en not_active Expired - Fee Related
-
2007
- 2007-04-30 US US11/796,849 patent/US7521066B2/en not_active Ceased
-
2010
- 2010-08-05 JP JP2010176721A patent/JP5436363B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-20 US US13/090,506 patent/USRE43295E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2449856C (en) | 2009-03-10 |
US20050112207A1 (en) | 2005-05-26 |
WO2002102311A2 (en) | 2002-12-27 |
EP1401396A4 (en) | 2009-08-05 |
JP5436363B2 (ja) | 2014-03-05 |
US7521066B2 (en) | 2009-04-21 |
KR100915741B1 (ko) | 2009-09-04 |
EP1401396A2 (en) | 2004-03-31 |
USRE43295E1 (en) | 2012-04-03 |
IL159119A0 (en) | 2004-05-12 |
US20070203166A1 (en) | 2007-08-30 |
JP2010248269A (ja) | 2010-11-04 |
US7387790B2 (en) | 2008-06-17 |
US7220428B2 (en) | 2007-05-22 |
CA2449856A1 (en) | 2002-12-27 |
IL159119A (en) | 2009-02-11 |
WO2002102311A3 (en) | 2003-03-27 |
US20030017197A1 (en) | 2003-01-23 |
MXPA03011593A (es) | 2005-03-07 |
KR20040025685A (ko) | 2004-03-24 |
AU2002322104C1 (en) | 2003-01-02 |
JP2005500293A (ja) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111491666B (zh) | 用于处理灼伤的局部用组合物 | |
BR0210994A (pt) | Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células | |
CY1121447T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης | |
ES2156421T3 (es) | Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica. | |
CN111683653A (zh) | 用于局部递送的方法和组合物 | |
BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
IL160015A0 (en) | Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases | |
WO2005044179A3 (en) | Formulations containing astragalus extracts and uses thereof | |
TW202128610A (zh) | 醫藥調配物 | |
BRPI0117180B8 (pt) | composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior | |
TW201039835A (en) | Chlorine dioxide treatment for biological tissue | |
DE59902270D1 (de) | Feuchtigkeitsaktivierbares therapeutisches system | |
JP2022552017A (ja) | 抗菌オルガノシラン | |
CN102369004A (zh) | 银屑病的治疗 | |
BR0312664A (pt) | Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo | |
EA200600468A1 (ru) | Биполярные транс-каротиноидные соли и их применение | |
Qothrunnadaa et al. | Patches for acne treatment: an update on the formulation and stability test | |
GB2569682A (en) | Composition | |
BR0109570A (pt) | Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdas | |
CN116999434A (zh) | HDAC5激活剂Gboxin在制备促进皮肤创面愈合的药物中的用途 | |
WO2011101868A2 (en) | Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof | |
SE9903610D0 (sv) | Novel compounds II | |
Hellberg et al. | Researchers Learn why Some Platinum Drugs Damage Ear Tissue | |
AR046841A1 (es) | Combinaciones para el tratamiento de enfermedades proliferativas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 9/00, A61K 9/51 Ipc: A61K 9/00 (2011.01), A61K 9/51 (2011.01), A61P 35/ |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 11A E 12A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |